Related Projects

Projects directly related to PARADISE

HELICAL includes TCD (coordinating, both TTMI and ADAPT), Firalis, KTH and i-HD. It has yielded important preliminary results in transcriptomics, autoantibodies and flow-cytometric markers, all of which are key inputs to PARADISE. HELICAL ended in 2022, with no risk of double-funding.

FAIRVASC includes TCD (again, coordinating, both TTMI and ADAPT), VIA and i-HD, and focuses on semantic-web data integration for national vasculitis registries. The FAIRVASC RDF ‘uplift’ platform will be reconfigured and customised for PARADISE.

AVERT is a TCD-led (TTMI and ADAPT) national project, in collaboration with VIA, capturing patient reported outcomes in the provision of better  and more personalised vasculitis care. The patient Mpower smart-phone app was originally developed in the AVERT project and will be adapted for use in PARADISE. 

Projects informing PARADISE

  6. VIA: RainDRoP- Rare Disease Research Partnership: identifying           research priorities for rare disease in Ireland, Nov.2018- June 2019. Involving patients, families, healthcare professionals and policy makers. Funded by the Irish Government Health Research Board.

TCD-TTMI and VIA: ERN RITA Patient Journeys Project: Started in 2021 as  part of work within ERN RITA – RIPAG. Each stream investigates the patient journey for different conditions across Europe to establish a template of the condition-specific Patient Journey. This will then be used to help guide future Clinical Guidelines and Care Pathways. 


i-HD: IMI2 HIPPOCRATES: development of personalised treatment strategies in Psoriatic Arthritis through large scale clinical, image and molecular data analysis. 


i-HD: H2020 GenoMed4All: Combining genomic, clinical data and other “omics” health data in personalised medicine for haematological disease. i~HD has a role in the ethics of AI development which offers insights into ethical and trustworthiness issues, data bias and quality, that we bring into PARADISE. 



Firalis: IMI SAFE-T: predictive models for drug-induced damage to kidney, liver and vascular systems. Firalis played a leading role in the creation and delivery of this project, which led to an FDA Letter of Support for five new liver safety biomarkers.


CUC: Digit-HeaL (Croatian Science Foundation)- “(New) Ethical and Social Challenges of Digital Technologies in the Healthcare Domain” – analysis of the ELSA aspects of digital technologies (i.e., Big data, Artificial intelligence etc.) in healthcare.


 UF: H2020 DynaMORE: Techniques for individualised prediction based on a combination of baseline characterisation and longitudinal follow-up data. Deep learning techniques were developed for uncovering groups of individuals and explaining different longitudinal trajectories observed for these using regularised regression techniques. 


Partager :